ASCO has become a little more interesting for prostate cancer. Today's item is about a mega-analysis that confirms that the site of metastatic tumors will powerfully predict overall survival (OS) among men with metastatic castration resistant prostate cancer (mCRPC). Older and smaller studies had previously suggested that the metastatic site is prognostic for OS. This [...]
Better prediction tools to predict treatment outcome in men with metastatic castration-resistant prostate cancer (mCRPC) should significantly improve treatment outcomes. Without good predictive measures we often don't know when is the optimum time to stop a therapy and move to another. This means that we might maturely stop an effective treatment losing the effectiveness of [...]
The prognosis of patients with advanced prostate cancer who have lymph node metastasis depends on the number of positive lymph nodes removed and Gleason score of the primary tumor. Bilateral pelvic lymph node dissection should be performed in intermediate- and high-risk patients to identify those with minimal nodal burden who may benefit the most from [...]
